Last week, shares of Immune Pharmaceuticals (IMNP) spiked in response to Jazz Pharma’s acquisition of Celator Pharma for $1.5 billion. Celator is developing VYXEOS™, a liposome injection of cytarabine + daunorubicin for patients with high-risk (secondary) acute myeloid leukemia (AML). Back in March 2016, Celator announced Phase 3 data showing its formulation to be vastly…
A team of researchers from Gothenburg University in Sweden presented data from a Phase 4 study on Ceplene® earlier this week at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA. These data could have a profound impact on future use of the drug in elderly patients with Acute Myeloid Leukemia (AML)….
Over the past several months, Immune Pharmaceuticals (IMNP) has aggressively expanded its efforts in oncology. The company has a two-fold strategy with its oncology pipeline, develop a platform of next-generation nanoparticle cytotoxic agents and bispecific antibodies, and resurrect legacy drug candidates acquired via the company’s acquisition of EpiCept in late 2013. If successful, Immune’s desire…
On Monday, February 8, 2016, at the BioCEO conference, Immune Pharmaceuticals Inc. (IMNP) made available a new investor presentation for shareholders that lays out the company’s key goals for 2016. Despite the precipitous decline in biotech stocks over the past three months, which no doubt has hit shares of Immune disproportionately hard, management remains aggressive in…
On December 14, 2015, Immune Pharmaceuticals (IMNP) provided a brief update for investors on the status of its preclinical bi-specific antibodies platform. As a reminder, outside of the lead immuno-inflammation focus with Phase 2 Bertilimumab for Bullous Pemphigoid and Ulcerative Colitis, Immune has a preclinical immuno-oncology program that consists of NanomAbs and bi-specific antibodies. Investors…